Showing 161 - 177 results of 177 for search '"uveitis"', query time: 0.04s Refine Results
  1. 161

    An analysis of heavy silicone oil treatment for inferior proliferative vitreoretinopathy by Maximilian Hammer, Amanda Ie, Katharina Eibenberger, Gerd Uwe Auffarth, Kanmin Xue

    Published 2025-01-01
    “…Inflammatory complications, such as anterior uveitis, were rare and any cystoid macular oedema was transient. …”
    Get full text
    Article
  2. 162

    Early Results with a New Posterior Chamber Phakic Intraocular Lens in Patients with High Myopia by Dilek Yaşa, Ufuk Ürdem, Alper Ağca, Yusuf Yildirim, Burçin Kepez Yildiz, Nilay Kandemir Beşek, Ulviye Yiğit, Ahmet Demirok

    Published 2018-01-01
    “…No significant cataract formation, significant endothelial cell loss, glaucoma, uveitis, or any other vision-threatening complication was observed. …”
    Get full text
    Article
  3. 163

    Update on the Medical Management of Gastrointestinal Behçet’s Disease by Giuseppe Lopalco, Donato Rigante, Vincenzo Venerito, Claudia Fabiani, Rossella Franceschini, Michele Barone, Giovanni Lapadula, Mauro Galeazzi, Bruno Frediani, Florenzo Iannone, Luca Cantarini

    Published 2017-01-01
    “…Behçet’s disease (BD) is a multisystemic disorder of unknown etiology mainly defined by recurrent oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis, all of which represent the “stigmata” of disease. …”
    Get full text
    Article
  4. 164

    Orbital lesion (pseudotumor and dacryoadenitis) is a manifestation of systemic sarcoidosis by E.A. Burylova, L.A. Mamaeva, A.S. Berdnikova, O.K. Fedorova

    Published 2021-03-01
    “…Chest CT is required to identify respiratory diseases when sarcoidosis manifests as uveitis or granulomatous orbital inflammation. Multidisciplinary diagnostic and treatment approach to suspected sarcoidosis provides timely verified diagnosis and management strategy. …”
    Get full text
    Article
  5. 165

    A real-world Pharmacovigilance study of brodalumab based on the FDA adverse event reporting system by Ke He, Kaidi Zhao, Tingyi Yin, Meng Liu, Jiashu Liu, Wenqian Du, Xinyi Liu, Baochen Cheng, Dewu Zhang, Yan Zheng

    Published 2025-01-01
    “…Additionally, we found potential adverse reactions not noted on the drug’s label that exhibited positive signals, including depression, increased blood pressure, peripheral swelling, gait disturbance, inability to walk, stress, myocardial infarction, sepsis, uveitis, nephrolithiasis, and interstitial lung disease. …”
    Get full text
    Article
  6. 166
  7. 167

    Comparative evaluation of funduscopy, PCR and serology in the diagnosis of ocular toxoplasmosis at ECWA Eye Hospital, Kano by Biodun Bintu Adebakin, Mayor Orezime Atima, Ugbede Idakwo, Jamilu Abubakar Bala, Alhasan Sharif Abdullahi, Auwal Bello Muhammad, Jah Douglas Pam, Emeka John Dingwoke, Florence Olufunke Darda

    Published 2025-01-01
    “…Objective Ocular toxoplasmosis, caused by Toxoplasma gondii, is a significant cause of posterior uveitis and vision impairment globally. Accurate diagnosis is essential to prevent retinal damage and optimise treatment. …”
    Get full text
    Article
  8. 168

    Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review by Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio

    Published 2025-01-01
    “…The major comorbidities recorded were fibromyalgia (33% of patients), recurrent bilateral anterior uveitis, and autoimmune thyroiditis with hypothyroidism (both 13% of the patients). …”
    Get full text
    Article
  9. 169

    Safety during surgical resection of the sclera in patients with primary and secondary glaucoma by A.Yu. Kazantzeva, E.A. Korchuganova

    Published 2024-09-01
    “…Among the complications after cyclodestructive intervention, uveitis was most common in patients with SPTG (21%). …”
    Get full text
    Article
  10. 170

    Peripapillary retinal nerve fiber layer and ganglion cell complex in Alzheimer’s disease by R.N. Gulieva

    Published 2020-06-01
    “…Exclusion criteria were ametropia greater than 5 diopters or axial length more than 25 mm, severe dementia, cerebrovascular disorders, metabolic and mental disorders, glaucoma, uveitis, retinal diseases, diabetes, and anamnestic stroke. …”
    Get full text
    Article
  11. 171

    Technique and long-term results of surgical resection of sclera in patients with primary glaucoma by E.A. Korchuganova, O.A. Rumyantseva, A.Yu. Kazantzeva

    Published 2018-09-01
    “…The operation is not followed by postoperative complications typical for glaucoma surgery, such as hyphema, hemophthalmia, ciliophorous detachment, uveitis.<br> <b>Conclusion</b>: the surgery is indicated for the patients with advanced stages of glaucoma, including residual visual functions, as well as on a single eye. …”
    Get full text
    Article
  12. 172

    Surgical stimulation of uveoscleral outflow is an alternative to cyclodestructive procedures by E.A. Korchuganova, A.Yu. Kazantzeva

    Published 2021-03-01
    “…In contrast, postoperative complications (choroidal effusion, hyphema, and uveitis) were reported in 14% of patients after TSCPC. …”
    Get full text
    Article
  13. 173

    Comparative Study on the Efficacy and Safety of Tumor Resection in Vitrectomy for Retinal Vasoproliferative Tumors by Bin Zheng, Yan Chen, Lifeng Chen, Huan Chen, Jingwei Zheng, Feng Chen, Zongming Song, Lin Fu, Xuting Hu, Jiandong Pan, Hengli Lian, Lijun Shen, Qiuming Li

    Published 2019-01-01
    “…Of the retinal diseases, the epiretinal membrane was the most common, followed by vitreous hemorrhage, uveitis, subretinal fluid, and so on. Compared with the baseline BCVA, it improved more at postoperative 6 months and the last visit in Group R than in Group C (P=0.006 and P=0.033). …”
    Get full text
    Article
  14. 174

    Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and i... by Sofia Ramiro, Désirée van der Heijde, Atul Deodhar, Xenofon Baraliakos, Denis Poddubnyy, Lianne S Gensler, Helena Marzo-Ortega, Natasha de Peyrecave, Victoria Navarro-Compán, Tetsuya Tomita, Carmen Fleurinck, Ute Massow, Thomas Vaux

    Published 2025-01-01
    “…Active inflammatory bowel disease and anterior uveitis EAIRs were 0.8 and 0.7, respectively. 202/303 (66.7%) patients completed Week 256. 42 (13.9%) patients discontinued treatment due to TEAEs.Efficacy at Week 48 was maintained for 5 years. …”
    Get full text
    Article
  15. 175

    Therapeutic applications of artemisinin in ophthalmic diseases by Hao Sun, Ping Zhao, Lianghui Zhao, Zhizhong Zhao, Haoyu Chen, Cong Ren, Bin Guo

    Published 2025-01-01
    “…To better explore and perfect the mechanism of action of artemisinin in ophthalmic diseases, and to better promote the clinical application of artemisinin, this study reviews the latest progress of artemisinin treatment for uveitis, uveal melanoma, age-related macular degeneration, diabetic retinopathy, ocular neovascularization, and dry eye, and it will provide theoretical support for the large-scale application of artemisinin in ophthalmic diseases in the future.…”
    Get full text
    Article
  16. 176

    Clinical Characteristics and Treatment Options of Peripheral Spondyloarthritis by ZENG Lulu, JI Xiaojian, HU Lidong, HU Jiawen, ZHANG Yinan, ZHANG Jiaxin, LIU Xingkang, YANG Shiwei, HUANG Feng

    Published 2024-12-01
    “…Compared to axSpA patients, pSpA1 patients(excluding psoriatic arthritis) did not show significant differences in the prevalence of psoriasis, uveitis, family history of psoriasis, or the use of bDMARDs, but the subgroup analysis of other variables was consistent with the results of pSpA patients.ConclusionspSpA patients tend to have a later onset of disease, a lower proportion of male and HLA-B27 positivity, more associated peripheral arthritis, dactylitis, psoriasis, and a more common family history of psoriasis. …”
    Get full text
    Article
  17. 177